

COSTS AND PRESCRIPTION PATTERNS OF PATIENTS WITH PSORIATIC ARTHRITIS AND ITS ASSOCIATED COSTS

Santos-Moreno P¹, Villarreal Peralta L², Cabrera M¹, Alvis Zakzuk N³, Buitrago-Garcia D⁴

¹Biomab, Center for Rheumatoid Arthritis, Bogota, Colombia, ²Biomab, Bogota, Colombia, ³ALZAK Foundation, Cartagena, Colombia, ⁴Fundación Universitaria de Ciencias de la Salud-FUCS, BOGOTÁ, Colombia

1

DISCLOSURE

- Pedro Santos-Moreno has received research grants, consulting fees and fees as speaker from Abbott, Abbvie, Biopas, Bristol-Myers Squibb, Roche pharmac, Pfizer inc, Janssen pharma, Sanofi-Aventis pharma, Biopas labs.
- I am not mentioned in Panama papers

2

BACKGROUND

Psoriatic Arthritis

-Chronic Inflammatory musculoskeletal Disease.
-It is associated with psoriasis

-The condition affects the skin and joints with a significant impact on quality of life



Clinical Manifestations

Five Patterns of arthritis

Periarticular disease

Nail lesions
Skin lesions

Brockbank J, Gladman D. Diagnosis and management of psoriatic arthritis. Drugs. 2002;62(17):2447-57. Epub 2002/11/08.

3


Epidemiology

- Psoriatic arthritis (PsA) affects women and men equally, with an incidence of approximately 6 per 100,000 per year and a prevalence of approximately 1 to 2 per 1000 in the general population.
- Estimates of the prevalence of psoriatic arthritis among patients with psoriasis have ranged from 4% to 30%.
- Patients with PsA have a significant economic burden on the healthcare system, it has been associated with high costs related to the use of the biological therapy (more than 50% of patients).

Brockbank J, Gladman D. Diagnosis and management of psoriatic arthritis. Drugs. 2002;62(17):2447-57. Epub 2002/11/08.

4

GRAPPA recommendations for PsA treatment 2016



5

OBJECTIVE

We aimed to estimate and describe medication patterns and costs of therapy in patients with Psoriatic Arthritis in a Specialized Center in Colombia.

6

METHODS

Retrospective
cohort analysis
using real life
data

Patients were
followed under
T2T standards

[Multidisciplinary
approach*](#)

Descriptive
Epidemiology

Costs for therapy are
presented in US dollars at
the official average rate for
2018

7

Our Multidisciplinary Healthcare Program

Rheumatologist

Physiatrist

Psychologist


Dermatologist

Physiotherapist

Dietician

8

RESULTS



9

Trends in prescription


Biological DMARDs 50%

Conventional DMARDs 40%

Pain medications, NSAIDs, vitamins among others 10%


10

Trends in prescription



11

Average Costs of Therapy



Al Sawah S, et al. Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis. J of medical economics. 2017;20(9):982-90.

12

DISCUSION - CONCLUSIONS

- The consumption of resources in PsA is mainly related to the use of biological therapies.
- As other studies developed in countries such as the United States pharmaceutical costs represent the biggest part of the treatment of PsA specially when biological therapy is used.
- It confirms the findings of others studies where the condition represents a significant economic burden, which increases over time as the disease progresses.
- Further investigation should be focused on prescription scheme and economic burden in order to find strategies and treatment options that optimize health care resources and potentiate services for patients

13

References

1. McHugh N, Maguire A, Handel I, Tillett W, Morris J, Hawkins N, et al. Evaluation of the Economic Burden of Psoriatic Arthritis and the Relationship Between Functional Status and Healthcare Costs. *The Journal of rheumatology*. 2019. Epub 2019/08/17.
2. Brockbank J, Gladman D. Diagnosis and management of psoriatic arthritis. *Drugs*. 2002;62(17):2447-57. Epub 2002/11/08.
3. Al Sawah S, Foster SA, Goldblum OM, Malatestinic WN, Zhu B, Shi N, et al. Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis. *Journal of medical economics*. 2017;20(9):982-90. Epub 2017/06/22.

14